Satellos Bioscience Inc. Our mission is to develop revolutionary medicines that harness the body's natural ability to self-repair, providing innovative treatments for debilitating muscle disorders. Building upon the groundbreaking research of our founder and CSO, Dr.

Michael Rudnicki, we have identified and characterized a unique subset of muscle stem cells, known as satellite cells, capable of both self-renewal and regeneration. Leveraging our proprietary MyoReGenX™ discovery platform, we have made significant advances in understanding the regulation of these cells, uncovering regeneration deficits in conditions ranging from Duchenne muscular dystrophy to age-related muscle decline. Our leading drug program focuses on Duchenne, where impaired stem cell function hampers lifelong muscle regeneration.

By correcting this deficiency, we aim to enhance the quality and duration of life for patients. Founded in 2018 by biotechnology visionaries Mr. Frank Gleeson and Dr.

Michael Rudnicki, Satellos Bioscience has since completed a reverse takeover, raised capital, and begun trading on the TSX-V under the ticker MSCL (OTC:MSCLF). Join us in our pursuit of groundbreaking therapies that address progressive muscle loss and transform patients' lives